tbuckley/cabot-search huggingface dataset:
Tc-99m (V) DMSA Scintigraphy in Malignant Lymphoma
Authors: SHUNG-SHUNG SUN, FENG-JU CHUANG, CHIA-HUNG KAO
Journal: Clinical Nuclear Medicine (2002)

From the Department of Nuclear Medicine, China Medical College Hospital, Taichung, Taiwan Received for publication December 19, 2001. Revision accepted February 28, 2002. Reprint requests: Chia-Hung Kao, Department of Nuclear Medicine, China Medical College Hospital, No. 2, Yuh-Der Road, Taichung 404, Taiwan. E-mail: [email protected]
Abstract 58: Hyaluronan metabolism enhances the Warburg effect and provides an alternate energy source in the breast cancer microenvironment
Authors: Natalie K. Thomas, Mark Waltham, Lishanthi Udabage, Tracey J. Brown
Journal: Cancer Research (2010)

Abstract Introduction: A hallmark of cancer is a shift in cellular metabolism away from oxidative phosphorylation of glucose towards aerobic glycolysis thereby facilitating the rapid generation of energy required for proliferation. In breast cancer, the overproduction of hyaluronan (HA) is associated with poor disease outcomes where its metabolism is a finely regulated equilibrium between rapid synthesis and degradation. Synthetic products are involved in the structural integrity of the tumoral architecture while catabolic intermediates contribute to cell proliferation, neovascularisation and metastasis but little is known about their role in the generation of intratumoral energy. Methods: A hyaluronanhigh producing cell line was generated by the stable transfection of HAS2 into the ZR-75-1 breast cancer cell line. The HA metabolism and expression of the HA receptor, CD44 was characterised in the parental, vector- and HAS2-transfected cell lines. The effect of elevated HA synthesis on the glycolytic phenotype was determined by quantitation of phosphoinositide 3-kinase/Akt pathway activation, transketolase-like protein 1 (TKTL1), pyruvate kinase M2 (PKM2), glucose transporter 1 (GLUT1), aerobic glycolysis, cell proliferation and metastasis both in vitro and in vivo. Results: Compared to the controls, HAS2-transfected cells liberated up to 10-fold more HA and had increased expression of CD44s and CD44v9. The resultant increase in CD44-HA interactions mediated in vitro activation of the PI3K/Akt pathway, enhanced proliferation and metastatic capacity, increased propensity for aerobic glycolysis and a higher HA metabolic index. High levels of HA production conferred a characteristic glycolytic phenotype to HAS2 transfectants where Akt and TKTL1 were up-regulated and PKM2 reduced. Unlike the classic glycolytic phenotype, GLUT1 was not increased, but down-regulated 3-fold in the HAS2 cells. HA-induced enhancement of the glycolytic phenotype was confirmed in vivo by a &amp;gt;6 fold increase in endpoint tumor volume and reduced overall survival in an animal model of metastases. Conclusions: Elevated HA production confers an aggressive phenotype to breast cancer where CD44-HA interactions alter the metabolic fate of the cell driving it into an aerobic glycolytic pathway. This study has provided preliminary evidence that in highly proliferative breast cancer glucose may not be the sole catabolic substrate and hyaluronan may contribute to this process. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 58.
l -Folinic Acid Versus d,l -Folinic Acid in Rescue of High-Dose Methotrexate Therapy in Children
Authors: M C Etienne, A Thyss, Y Bertrand, R Touraine, H Rubie, A Robert, G Milano
Journal: JNCI Journal of the National Cancer Institute (1992)

Background: At this time, folinic acid (FA) is commercially available as the racemic mixture d, l -FA, whose biological activity is supported by natural /-FA. The administration of d,l -FA results in the accumulation of d -FA in plasma relative to the active l -FA form; in vitro studies have shown that d -FA can compete with the polyglutamation of methotrexate (MTX). Purpose: Our purpose was to compare, on a pharmacokinetic, biological, and clinical basis, the racemic mixture d, l -FA with the pure l -FA in rescue of high-dose MTX therapy (5 g/m 2 ) in children with acute lymphocytic leukemia (ALL). Methods: Eighteen children with ALL were entered in this trial, which was planned with a crossover design. Four cycles of MTX were administered to each patient, and rescue was achieved orally every 6 hours at a dose of 12 mg/m 2 for d,l -FA and 6 mg/m 2 for pure /-FA. The d, l -FA and l -FA rescues were alternated from one cycle to the next. d -FA, l -FA, and the active metabolite 5-methyltetrahydrofolate (5-MTHF) were measured in plasma using a stereospecific high-performance liquid chromatography assay. Results : Considering total active folate levels (/-FA + 5-MTHF), mean residual concentrations were similar for rescue by d,l-FA and l-FA, after two and six intakes, respectively: 92 and 186 nM for d,l-FA rescue versus 100 and 184 nM for l-FA rescue. Intra-individual comparison of total active folates (l-FA + 5-MTHF) did not show any significant difference between d,l-FA rescue and l-FA rescue. After administration of d,l-FA, the accumulation of d-FA in plasma was confirmed. For both types of FA rescue, MTX terminal half-lives were identical (average value, 13.9 hours). Considering each type of toxic effect (hematologic, hepatic, renal, and digestive), there was no significant difference in the proportion of toxic cycles following l -FA rescue or d,l -FA rescue. Conclusion : The administration of the pure l -FA, compared with the administration of the racemic mixture, results in comparable blood profiles of active folates and MTX, leads to equivalent treatment tolerance, and avoids the plasma accumulation of d -FA. [J Natl Cancer Inst 84:1190–1195, 1992]
Abstract 917: Polymorphic analysis of <i>MUC4</i> minisatellites and its relation to cancer
Authors: Se-Ra Lee, Se-Lyun Yoon, Myoung-Hyun Ahn, In-Sun Chu, Sun-Hee Leem
Journal: Cancer Research (2010)

Abstract The membrane-bound mucins belong to O-glycoproteins family and they are thought to play important biological roles in cell-cell and cell-matrix interactions, in cell signalling and in modulating biological properties of cancer cells. Among them, MUC4 is well characterized and their altered expression in cancer indicates an important role for these membrane-bound mucins in tumour progression and metastasis; however, their genomic levels are unclear because of complex genomic properties. In this study, we identified seven novel minisatellites from the entire MUC4 region and investigated how allelic variation in these minisatellites may affect susceptibility to cancers. We analyzed genomic DNA from the blood of normal healthy individuals and five (MUC4-MS2, MS3, MS4, MS6, MS7) among the seven minisatellites exhibited polymorphism. Furthermore, a case-control study was performed that compared genomic DNA from 351 cancer-free controls with DNA from individuals with 352 gastric cancers. A statistically significant association was identified between long alleles of MUC4-MS3 and the odds of gastric cancer: odds ratio (OR), 1.3; 95% confidence interval (CI), 1.02-1.59; and p = 0.03. Moreover, MUC4-MS3 alleles showed the highest heterozygosity (h = 0.74) among seven minisatellites that may play a role in its chromosomal instability. This idea was examined by comparing the polymorphic alleles of hypervariable MUC4-MS3 minisatellites in the blood and cancer tissues from 36 patients with gastric cancer and 27 patients with liver cancer. The frequency of rearrangement in MUC4-MS3 was shown each as 27% and 11% in gastric and liver cancer tissues. Furthermore, these rearrangements were detected significantly higher in long alleles than in short alleles. These observations suggest that the long MUC4-MS3 alleles could function as identifiers for risk of gastric cancer. Additionally, we suggest that minisatellite instability might be associated with MUC4 function in cancer cells. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 917.
AB0716 Pulmonary arterial hypertension in patients with primary sjÖgren’s syndrome
Authors: S. Kobak, S. Kalkan, B. Kirilmaz, E. Ercan
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Primary Sjögren's syndrome(pSS) is autoimmune disease, characterized with sicca symptoms and systemic involvement. Pulmonary involvement is main extraglandular feature. Pulmonary arterial hypertension(PAH) is frequently seen in many connective tissue diseases, mainly in systemic sclerosis. <h3>Objectives</h3> To evaluate the frequency of pulmonary arterial hypertension in patients with primary SS and possible correlation with clinical and laboratory findings. <h3>Methods</h3> 47 pSS patients diagnosed according to AECG criteria were included in the study. All of the patients were clinically and laboratory evaluated. Echocardiography was performed to evaluate pulmonary hypertension and cardiac involvement. Pulmonary arterial hypertension was defined as pulmonary arterial pressure(SPAP) &gt;30mm Hg with the patient at rest. <h3>Results</h3> 47pSS patients were included in the study. Of all patients, 2 were males and 45 were females. Mean age was 48 years and the mean disease duration was 5.5 years. Pulmonary arterial hypertension was recorded in 11(%23.4) patients. Among 11patients, five patients had SPAP&gt;35mmHg, six patients had SPAP 30-35mmHg. All of 11 patients with PAH were females. <h3>Conclusions</h3> Our study showed that pulmonary hypertension are highly frequent among patients with pSS. More investigations are needed to support our findings. <h3>References</h3> Gardiner P, Ward C, Allison A, Ashcroft J, Simpson W, Walters H et al (1993) Pleuropulmonary abnormalities in primary Sjogren's syndrome. J Rheumatol 20:831–837. Sato T, Matsubara O, Tanaka Y, Kasuga T (1993) Association of Sjogren's syndrome and primary pulmonary hypertension. Report of two cases and review of the literature. Hum Pathol 24:199–205. Chisholm DM, Mason DK (1968) Labial salivary gland biopsy in Sjogren's disease. J Clin Pathol 21:656–660. Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE et al (2002) Classification criteria for Sjogren's syndrome: a revised version of the European criteria proposed by the American–European Consensus Group. Ann Rheum Dis 61:554–558. <h3>Disclosure of Interest</h3> None Declared
111In-Octreotide Potential Pitfall Uptake of Laparoscopic Wedge Liver Biopsy
Authors: Ba Duong Nguyen
Journal: Clinical Nuclear Medicine (2013)

Somatostatin receptor scintigraphy may show benign In-octreotide uptake due to physiologic, inflammatory, or reactive processes. Awareness of these findings helps the imager to avoid pitfall interpretation of primary or secondary malignancies. To the list of previously reported potential false-positive findings of In-octreotide, the author adds a case of tracer uptake from laparoscopic wedge liver biopsy.
SAT0506 The Value of the 2010 ACR/Eular Rheumatoid Arthritis Classification Criteria for the Prognosis of Early Arthritis: Evaluation of Erosion Development with Ultrasonography
Authors: N. Inanc, F. Alibaz-Oner, M. Can, H. Direskeneli
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> The 2010 ACR/EULAR Rheumatoid Arthritis(RA) classification criteria was developed to diagnose the early arthritis patients who will progress destructive disease and to start early treatment. <h3>Objectives</h3> We aimed to investigate the value of these classification criteria for the prognosis of early arthritis patients with the evaluation of the longitudinal ultrasonographic(US) examination for the development of erosions. <h3>Methods</h3> The study included patients presenting with at least on)e swollen joints to “Early arthritis Clinic” between 2009 and 2012. The patients having symptom duration less than 24 months were recruited to the study. Clinical evaluation(tender/swollen joint counts, DAS28 and HAQ scores) and US examination of erosion at 2nd MCP, 5th MCP, 2nd PIP and 5th MTP joints were performed prospectively at the lateral approach longitudinally and transversally for the determination of the erosion score at baseline and 12months. <h3>Results</h3> A total of 71 patients (F/M:53/18) were included. The mean age was 38.2±14.2, mean symptom duration was 6.4 (0-24) months. At baseline assessment, 46.5% (n:33) of patients were classification as RA according to 2010 ACR/EULAR criteria and others were diagnosed as undiffererentiated arthritis(UA) after excluding other possible diagnosis. At baseline, higher percentage of patients whom was diagnosed as RA according to 2010 ACR/EULAR criteria (44% vs 23%, p= 0.072) were found to have erosive changes with the US examination. Furthermore, a tendency was observed for the progression of erosive disease, in terms of increased number of erosive joints, in patients diagnosed according to 2010 criteria vs patients diagnosed as UA (32% vs 10% p=0.072) at follow-up. Positive RF was also determined as a predictor of erosions by US (35% vs 11%, p=0.053). <h3>Conclusions</h3> Among patients with early arthritis fulfilling the 2010 ACR/EULAR RA criteria had erosive disease at diagnosis and increased frequency of erosions during the follow-up. Early evaluation of the joints by US can be used for the early detection of erosions which may predict the prognosis of RA. <h3>Disclosure of Interest</h3> None Declared
Abstract 2888A: Prevention of MAPK pathway by Brazilian medicinal plant, <i>Tabebuia avellanedae,</i> on peroxynitrite induced carcinogenesis
Authors: Harukuni Tokuda, Masafumi Kaneko, Mituaki Yamashita, Nobutaka Suzuki, Akira Iida
Journal: Cancer Research (2010)

Abstract The present study was carried out to examine the chemopreventive activity of natural Brazilian medicinal plant, Tabebuia avellanedae ext. and its components on peroxynitrite(PN) induced carcinogenesis. Tabebuia avellanedae,(TA) which is a plant that has been used for herbal medicine in South America and from Brazil to northern Argentina, is well known in traditional folk medicne used for the treatment of various disease during five hundred years. The inner bark of this plant produced in Brazil is distributed in Asia as a herb tea and healthy purpose. On the fundamental findings, this substance was observed the inhibitory effects against chemical carcinogenesis induced tumor initiating and promoting activity using two-stage mouse skin model. In the course of these studies, female SENCAR mouse (6 weeks of age) were treated topically with single dose of PN solution, followed by TPA twice a weekly for 20 weeks. Tumor incidences were 100% with 6 to 7 paillomas per mouse at end of experiment as positive control group. TA powder were orally fed with drinking water for only 2 weeks, before and after initiation and following promoting treatment with drinking water only, as test compounds. In our observations, TA and its components treated group cause about 60-70 % reduction in the average number of tumors per mouse after 20 weeks of experiment, respectively. Topical administration of TA and its components had much influence against PN induced expression stage. We postulate that these data suggeste possible role of a regulatory mechanism of chemopreventive activity in PN induced carcinogenesis. Employing Western blot analysis studies, we found that H-Ras, MEK-2 and p38 levels observed the effects against PN induced activation, and more detail Western blot analysis indicated a active decrease in p38 expression in the skin after TA treatment. Summary of our findings, we suggest that one target of TA and its component effects in mouse skin is the modulation or regulation of the MAPK signaling. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 2888A.
DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1
Authors: Yusuke Ogitani, Tetsuo Aida, Katsunobu Hagihara, Junko Yamaguchi, Chiaki Ishii, Naoya Harada, Masako Soma, Hiromi Okamoto, Masataka Oitate, Shingo Arakawa, Takehiro Hirai, Ryo Atsumi, Takashi Nakada, Ichiro Hayakawa, Yuki Abe, Toshinori Agatsuma
Journal: Clinical Cancer Research (2016)

An anti-HER2 antibody-drug conjugate with a novel topoisomerase I inhibitor, DS-8201a, was generated as a new antitumor drug candidate, and its preclinical pharmacologic profile was assessed.In vitro and in vivo pharmacologic activities of DS-8201a were evaluated and compared with T-DM1 in several HER2-positive cell lines and patient-derived xenograft (PDX) models. The mechanism of action for the efficacy was also evaluated. Pharmacokinetics in cynomolgus monkeys and the safety profiles in rats and cynomolgus monkeys were assessed.DS-8201a exhibited a HER2 expression-dependent cell growth-inhibitory activity and induced tumor regression with a single dosing at more than 1 mg/kg in a HER2-positive gastric cancer NCI-N87 model. Binding activity to HER2 and ADCC activity of DS-8201a were comparable with unconjugated anti-HER2 antibody. DS-8201a also showed an inhibitory activity to Akt phosphorylation. DS-8201a induced phosphorylation of Chk1 and Histone H2A.X, the markers of DNA damage. Pharmacokinetics and safety profiles of DS-8201a were favorable and the highest non-severely toxic dose was 30 mg/kg in cynomolgus monkeys, supporting DS-8201a as being well tolerated in humans. DS-8201a was effective in a T-DM1-insensitive PDX model with high HER2 expression. DS-8201a, but not T-DM1, demonstrated antitumor efficacy against several breast cancer PDX models with low HER2 expression.DS-8201a exhibited a potent antitumor activity in a broad selection of HER2-positive models and favorable pharmacokinetics and safety profiles. The results demonstrate that DS-8201a will be a valuable therapy with a great potential to respond to T-DM1-insensitive HER2-positive cancers and low HER2-expressing cancers. Clin Cancer Res; 22(20); 5097-108. ©2016 AACR.
379 ULTRA-DEEP PYROSEQUENCING OF BASIC CORE PROMOTER, PRECORE AND CORE REGIONS OF HEPATITIS B VIRUS TO STUDY VIRAL VARIABILITY AND QUASISPECIES COMPLEXITY
Authors: M. Homs, J. Gregori, M. Buti, D. Tabernero, S. Camós, R. Casillas, J. Quer, R. Esteban, F. Rodriguez-Frias
Journal: Journal of Hepatology (2013)
Clinically Silent Giant Parathyroid Adenoma
Authors: Domenico Rubello, Stefania Manente, Dario Casara, Davide Fiore, Maria Rosa Pelizzo, Brahm Shapiro, Pier Carlo Muzzio
Journal: Clinical Nuclear Medicine (2003)

RUBELLO, DOMENICO M.D.*; MANENTE, STEFANIA M.D.*; CASARA, DARIO M.D.*; FIORE, DAVIDE M.D.†; ROSA PELIZZO, MARIA M.D.‡; SHAPIRO, BRAHM M.D., PH.D.§; CARLO MUZZIO, PIER M.D.† Author Information
Abstract LB-378: Establishment of hepatic metastases in a steatotic microenvironment is enhanced by stromal derived MMP-12
Authors: Michael N. VanSaun, Alisha Mendonsa, In Kyu Lee, Lynn M. Matrisian, Lee Gorden
Journal: Cancer Research (2010)

Abstract Non-alcoholic fatty liver disease (NAFLD), encompassing steatosis and progression to non-alcoholic steatohepatitis (NASH) are liver disorders of increasing clinical significance. We have shown that hepatic steatosis establishes a permissive microenvironment for metastatic seeding and tumor progression in the liver. We have identified MMP-12 (macrophage metalloelastase) as an important molecular component associated with hepatic steatosis and steatohepatitis. Wildtype mice in the C57Bl/6 background were fed a 42% fat diet for three months to induce hepatic steatosis. Affymetrix microarray analysis was performed on steatotic vs. normal murine livers to determine candidate genes altered between these liver microenvironments. Our results noted 715 significant changes in gene expression, of which matrix metalloproteinase 12 was among the most significantly up regulated genes in the steatotic microenvironment. Importantly, we have detected an upregulation of MMP-12 in human steatotic and steatohepatitis samples. MMP-12 deficient mice gained weight and developed diet-induced hepatic steatosis similar to wildtype mice. To determine whether MMP-12 affected metastasis, normal and steatotic MMP-12 deficient mice were tested with an experimental metastasis model via splenic injection of MC38 tumor cells. The number of resultant tumors per unit of tissue area in wildtype steatotic livers showed a 25 fold increase compared to tumors in MMP-12 deficient mice. Comparison of tumors between regular diet livers in wildtype and MMP12−/−mice was not significant. Immunohistochemical staining for F4/80 showed a reduction in the number of positive cells in MMP-12 deficient steatotic livers. Conclusions: Modulation of host factors is known to be important in tissue/site specific susceptibility to cancer metastases. MMP-12 can influence immune-mediated injury response by processing latent TNF alpha and regulating macrophage recruitment. Upregulation of matrix metalloproteinase 12 suggest a role for this protease in inflammatory mediated events in the distinct microenvironments of steatosis and steatohepatitis. The molecular mechanisms underlying the decreased establishment of metastatic tumors in MMP-12 deficient mice requires further investigation. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr LB-378.
Improved Glucose Tolerance with High Carbohydrate Feeding in Mild Diabetes
Authors: John D. Brunzell, Roger L. Lerner, William R. Hazzard, Daniel Porte, Edwin L. Bierman
Journal: New England Journal of Medicine (1971)

To evaluate the effect of increased dietary carbohydrate in diabetes mellitus, glucose and immunoreactive insulin levels were measured in normal persons and subjects with mild diabetes maintained on basal (45 per cent carbohydrate) and high carbohydrate (85 per cent carbohydrate) diets. Fasting plasma glucose levels fell in all subjects and oral glucose tolerance (0 to 120-minute area) significantly improved after 10 days of high carbohydrate feeding. Fasting insulin levels also were lower on the high carbohydrate diet; however, insulin responses to oral glucose did not significantly change. These data suggest that the high carbohydrate diet increased the sensitivity of peripheral tissues to insulin.